Ludger is an industry leader specialising in glycomics and glycoanalytical technology to support biopharmaceutical realisation and translational medicine.
Their technology originated at the University of Oxford, UK and is used in the quality control of FDA- and EMA-approved biopharmaceuticals worldwide. Ludger provides Glycan analytical services, kits and reagents for detailed characterisation of glyco-conjugates. In addition, they also provide support for validation studies and consultation services for biopharma and regulators. Ludger’s technology can be used to support IND submissions.
Ludger has been operating since 1999 and has successfully established close contacts and serviced their client base including leading pharmaceutical, biotechnology companies as well as academic research institutions throughout the world. Ludger's Head Office, R&D, analytical services and production laboratories are located within the U.K Bioscience 'golden triangle' (Oxford-Cambridge-London) at the Culham Science Centre, Oxfordshire, UK and they have a subsidiary office in Shanghai, China.
Ludger is ISO9001 Registered and operates a Quality Management System (QMS) which covers all aspects of the company's operations, including glycan analysis contract services, and is based on the ISO 9001:2015 registration framework.
Role within INTERCEPT
The scientists at Ludger will be part of the biomarker development and validation teams in INTERCEPT. They will focus on glycomics analysis of presented samples and their labs will identify and quantify the glycans present in patient related samples.
Main contacts
Dr Daniel Spencer
Head of Development
Dr Jack Cheeseman
Senior Scientist - Glycomics
Paulina Urbanowicz
Lead Scientist – Bioinformatics and Glycomics
Georgia Elgood-Hunt
Bioinformatician
Carlos Perez
Scientist - Glycomics